Respirium

From Bidder’s Statement page 13

”Combination of the two entities will allow accepting Adherium Shareholders (other than Ineligible Foreign Shareholders) to benefit from Respiri's ability (via Respiri's 'wheezo' device leveraging Adherium's technology) to immediately target the total addressable market of US$1.5 billion in the USA.”

’to immediately target’ - this would bring forward the entry into the USA market by a year!

The benefits for both entities would be enormous if an agreeable outcome on merging can be reached - not only financially but with a more fine tuned monitoring of asthma.

And don’t you like “Respirium”!! - how can we go wrong with a name like that!

Cheers